Newer medical therapies for metastatic soft tissue sarcoma

References

• Fletcher CDM, Bridge JA, Hogendoorn P et al. WHO classification of tumours of soft tissue and bone.Vol. 5. IARC; 2013.
   Google Scholar
• Buesa JM, Mouridsen HT, van Oosterom AT, et al. High-dose DTIC in advanced soft-tissue sarcomas in the adult. A phase II study of the E.O.R.T.C. Soft Tissue and Bone Sarcoma Group. Ann Oncol Off J Eur Soc Med Oncol ESMO. 1991 Apr;2(4):307–309.
   PubMed Web of Science ®Google Scholar
• García-Del-Muro X, López-Pousa A, Maurel J, et al. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. J Clin Oncol Off J Am Soc Clin Oncol. 2011 Jun 20;29(18):2528–2533.
   PubMed Web of Science ®Google Scholar
• Lorigan P, Verweij J, Papai Z, et al. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol Off J Am Soc Clin Oncol. 2007 Jul 20;25(21):3144–3150.
   PubMed Web of Science ®Google Scholar
• Maki RG, Wathen JK, Patel SR, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol Off J Am Soc Clin Oncol. 2007 Jul 1;25(19):2755–2763.
   PubMed Web of Science ®Google Scholar
• Zucali PA, Bertuzzi A, Parra HJS, et al. The “old drug” dacarbazine as a second/third line chemotherapy in advanced soft tissue sarcomas. Invest New Drugs. 2008 Apr;26(2):175–181.
   PubMed Web of Science ®Google Scholar
• Van Glabbeke M, van Oosterom AT, Oosterhuis JW, et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens – a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol Off J Am Soc Clin Oncol. 1999 Jan;17(1):150–157.
   PubMed Web of Science ®Google Scholar
• van der Graaf WTA, Blay J-Y, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Lond Engl. 2012 May 19;379(9829):1879–1886.
   PubMed Web of Science ®Google Scholar
• Cuevas C, Francesch A. Development of Yondelis® (trabectedin, ET-743). A semisynthetic process solves the supply problem. Nat Prod Rep. 2009 Mar;26(3):322–337.
   PubMed Web of Science ®Google Scholar
• Hurley LH, Zewail-Foote M. The antitumor agent ecteinascidin 743: characterization of its covalent DNA adducts and chemical stability. Adv Exp Med Biol. 2001;500:289–299.
   PubMed Web of Science ®Google Scholar
• Di Giandomenico S, Frapolli R, Bello E, et al. Mode of action of trabectedin in myxoid liposarcomas. Oncogene. 2014 Oct 30;33(44):5201–5210.
   PubMed Web of Science ®Google Scholar
• Forni C, Minuzzo M, Virdis E, et al. Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. Mol Cancer Ther. 2009 Feb;8(2):449–457.
   PubMed Web of Science ®Google Scholar
• Bueren-Calabuig JA, Giraudon C, Galmarini CM, et al. Temperature-induced melting of double-stranded DNA in the absence and presence of covalently bonded antitumour drugs: insight from molecular dynamics simulations. Nucleic Acids Res. 2011 Oct;39(18):8248–8257.
   PubMed Web of Science ®Google Scholar
• Aune GJ, Takagi K, Sordet O, et al. Von Hippel-Lindau-coupled and transcription-coupled nucleotide excision repair-dependent degradation of RNA polymerase II in response to trabectedin. Clin Cancer Res Off J Am Assoc Cancer Res. 2008 Oct 15;14(20):6449–6455.
   PubMed Web of Science ®Google Scholar
• Herrero AB, Martín-Castellanos C, Marco E, et al. Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin. Cancer Res. 2006 Aug 15;66(16):8155–8162.
   PubMed Web of Science ®Google Scholar
• Germano G, Frapolli R, Simone M, et al. Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res. 2010 Mar 15;70(6):2235–2244.
   PubMed Web of Science ®Google Scholar
• Allavena P, Signorelli M, Chieppa M, et al. Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production. Cancer Res. 2005 Apr 1;65(7):2964–2971.
   PubMed Web of Science ®Google Scholar
• Demetri GD, Chawla SP, von Mehren M, et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol Off J Am Soc Clin Oncol. 2009 Sep 1;27(25):4188–4196.
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, López-Pousa A, Poveda A, et al. Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone. Invest New Drugs. 2012 Apr;30(2):729–740.
   PubMed Web of Science ®Google Scholar
• Twelves C, Hoekman K, Bowman A, et al. Phase I and pharmacokinetic study of YondelisTM (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours. Eur J Cancer. 2003 Sep 1;39(13):1842–1851.
   PubMed Web of Science ®Google Scholar
• Delaloge S, Yovine A, Taamma A, et al. Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients – preliminary evidence of activity. J Clin Oncol Off J Am Soc Clin Oncol. 2001 Mar 1;19(5):1248–1255.
   PubMed Web of Science ®Google Scholar
• Le Cesne A, Blay JY, Judson I, et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol Off J Am Soc Clin Oncol. 2005 Jan 20;23(3):576–584.
   PubMed Web of Science ®Google Scholar
• Demetri GD, von Mehren M, Jones RL, et al. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial. J Clin Oncol Off J Am Soc Clin Oncol. 2016 Mar 10;34(8):786–793.
   PubMed Web of Science ®Google Scholar
• Garcia-Carbonero R, Supko JG, Manola J, et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol Off J Am Soc Clin Oncol. 2004 Apr 15;22(8):1480–1490.
   PubMed Web of Science ®Google Scholar
• Yovine A, Riofrio M, Blay JY, et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol Off J Am Soc Clin Oncol. 2004 Mar 1;22(5):890–899.
   PubMed Web of Science ®Google Scholar
• Kawai A, Araki N, Sugiura H, et al. Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study. Lancet Oncol. 2015 Apr;16(4):406–416.
   PubMed Web of Science ®Google Scholar
• Blay J-Y, Italiano A, Ray-Coquard I, et al. Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program. BMC Cancer. 2013;13:64.
   PubMed Web of Science ®Google Scholar
• Garcia-Carbonero R, Supko JG, Maki RG, et al. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. J Clin Oncol Off J Am Soc Clin Oncol. 2005 Aug 20;23(24):5484–5492.
   PubMed Web of Science ®Google Scholar
• Bui-Nguyen B, Butrynski JE, Penel N, et al. A phase IIb multicentre study comparing the efficacy of trabectedin to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma: the TRUSTS trial. Eur J Cancer Oxf Engl 1990. 2015 Jul;51(10):1312–1320.
   PubMed Web of Science ®Google Scholar
• Pautier P, Floquet A, Chevreau C, et al. Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial. Lancet Oncol. 2015 Apr;16(4):457–464.
   PubMed Web of Science ®Google Scholar
• Grosso F, D’Incalci M, Cartoafa M, et al. A comprehensive safety analysis confirms rhabdomyolysis as an uncommon adverse reaction in patients treated with trabectedin. Cancer Chemother Pharmacol. 2012 Jun;69(6):1557–1565.
   PubMed Web of Science ®Google Scholar
• Potti A, Ganti AK, Tendulkar K, et al. Determination of vascular endothelial growth factor (VEGF) overexpression in soft tissue sarcomas and the role of overexpression in leiomyosarcoma. J Cancer Res Clin Oncol. 2004 Jan;130(1):52–56.
   PubMed Web of Science ®Google Scholar
• Yudoh K, Kanamori M, Ohmori K, et al. Concentration of vascular endothelial growth factor in the tumour tissue as a prognostic factor of soft tissue sarcomas. Br J Cancer. 2001 Jun 15;84(12):1610–1615.
   PubMed Web of Science ®Google Scholar
• Keisner SV, Shah SR. Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma. Drugs. 2011 Mar 5;71(4):443–454.
   PubMed Web of Science ®Google Scholar
• van Leeuwen RWF, van Gelder T, Mathijssen RHJ, et al. Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective. Lancet Oncol. 2014 Jul;15(8):e315–e326.
   PubMed Web of Science ®Google Scholar
• Budha NR, Frymoyer A, Smelick GS, et al. Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH-dependent solubility the Achilles heel of targeted therapy? Clin Pharmacol Ther. 2012 Aug;92(2):203–213.
   PubMed Web of Science ®Google Scholar
• Sleijfer S, Ray-Coquard I, Papai Z, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC study 62043). J Clin Oncol Off J Am Soc Clin Oncol. 2009 Jul 1;27(19):3126–3132.
   PubMed Web of Science ®Google Scholar
• Valverde CM, Martin Broto J, Lopez-Martin JA, et al. Phase II clinical trial evaluating the activity and tolerability of pazopanib in patients (pts) with advanced and/or metastatic liposarcoma (LPS): a joint Spanish Sarcoma Group (GEIS) and German Interdisciplinary Sarcoma Group (GISG) Study – NCT01692496. ASCO Meet Abstr. 2016 May 20;34(15_suppl):11039.
   Google Scholar
• Towle MJ, Salvato KA, Budrow J, et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res. 2001 Feb 1;61(3):1013–1021.
   PubMed Web of Science ®Google Scholar
• Uemura D, Takahashi K, Yamamoto T, et al. Norhalichondrin A: an antitumor polyether macrolide from a marine sponge. J Am Chem Soc. 1985;107:4796–4798.
   Web of Science ®Google Scholar
• Jordan MA, Kamath K, Manna T, et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther. 2005 Jul;4(7):1086–1095.
   PubMed Web of Science ®Google Scholar
• Shetty N, Gupta S. Eribulin drug review. South Asian J Cancer. 2014;3(1):57–59.
   PubMedGoogle Scholar
• Schöffski P, Ray-Coquard IL, Cioffi A, et al. Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes. Lancet Oncol. 2011 Oct;12(11):1045–1052.
   PubMed Web of Science ®Google Scholar
• Schöffski P, Chawla S, Maki RG, et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet Lond Engl. 2016 Apr 16;387(10028):1629–1637.
   PubMed Web of Science ®Google Scholar
• Funahashi Y, Okamoto K, Adachi Y, et al. Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models. Cancer Sci. 2014 Oct;105(10):1334–1342.
   PubMed Web of Science ®Google Scholar
• George S, Merriam P, Maki RG, et al. Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol Off J Am Soc Clin Oncol. 2009 Jul 1;27(19):3154–3160.
   PubMed Web of Science ®Google Scholar
• Mahmood ST, Agresta S, Vigil CE, et al. Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma. Int J Cancer. 2011 Oct 15;129(8):1963–1969.
   PubMed Web of Science ®Google Scholar
• Hensley ML, Sill MW, Scribner DR, et al. Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study. Gynecol Oncol. 2009 Dec;115(3):460–465.
   PubMed Web of Science ®Google Scholar
• Stacchiotti S, Negri T, Libertini M, et al. Sunitinib malate in solitary fibrous tumor (SFT). Ann Oncol Off J Eur Soc Med Oncol ESMO. 2012 Dec;23(12):3171–3179.
   PubMed Web of Science ®Google Scholar
• Stacchiotti S, Tamborini E, Marrari A, et al. Response to sunitinib malate in advanced alveolar soft part sarcoma. Clin Cancer Res Off J Am Assoc Cancer Res. 2009 Feb 1;15(3):1096–1104.
   PubMed Web of Science ®Google Scholar
• Ghose A, Tariq Z, Veltri S. Treatment of multidrug resistant advanced alveolar soft part sarcoma with sunitinib. Am J Ther. 2012 Jan;19(1):e56–e58.
   PubMed Web of Science ®Google Scholar
• Stacchiotti S, Negri T, Zaffaroni N, et al. Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2011 Jul;22(7):1682–1690.
   PubMed Web of Science ®Google Scholar
• Stacchiotti S, Dagrada GP, Morosi C, et al. Extraskeletal myxoid chondrosarcoma: tumor response to sunitinib. Clin Sarcoma Res. 2012;2(1):22.
   PubMedGoogle Scholar
• Stacchiotti S, Pantaleo MA, Astolfi A, et al. Activity of sunitinib in extraskeletal myxoid chondrosarcoma. Eur J Cancer Oxf Engl 1990. 2014 Jun;50(9):1657–1664.
   PubMed Web of Science ®Google Scholar
• Maki RG, D’Adamo DR, Keohan ML, et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol Off J Am Soc Clin Oncol. 2009 Jul 1;27(19):3133–3140.
   PubMed Web of Science ®Google Scholar
• von Mehren M, Rankin C, Goldblum JR, et al. Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas. Cancer. 2012 Feb 1;118(3):770–776.
   PubMed Web of Science ®Google Scholar
• Ray-Coquard I, Italiano A, Bompas E, et al. Sorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO). Oncologist. 2012;17(2):260–266.
   PubMed Web of Science ®Google Scholar
• Chevreau C, Le Cesne A, Ray-Coquard I, et al. Sorafenib in patients with progressive epithelioid hemangioendothelioma: a phase 2 study by the French Sarcoma Group (GSF/GETO). Cancer. 2013 Jul 15;119(14):2639–2644.
   PubMed Web of Science ®Google Scholar
• Bompas E, Le Cesne A, Tresch-Bruneel E, et al. Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO). Ann Oncol Off J Eur Soc Med Oncol ESMO. 2015 Oct;26(10):2168–2173.
   PubMed Web of Science ®Google Scholar
• Wedge SR, Kendrew J, Hennequin LF, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res. 2005 May 15;65(10):4389–4400.
   PubMed Web of Science ®Google Scholar
• Fox E, Aplenc R, Bagatell R, et al. A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors. J Clin Oncol Off J Am Soc Clin Oncol. 2010 Dec 10;28(35):5174–5181.
   PubMed Web of Science ®Google Scholar
• Gardner K, Judson I, Leahy M, et al. Activity of cediranib, a highly potent and selective VEGF signaling inhibitor, in alveolar soft part sarcoma. J Clin Oncol 27:15s,2009 (suppl;abstr 10523).
   Google Scholar
• Kummar S, Allen D, Monks A, et al. Cediranib for metastatic alveolar soft part sarcoma. J Clin Oncol Off J Am Soc Clin Oncol. 2013 Jun 20;31(18):2296–2302.
   PubMed Web of Science ®Google Scholar
• Judson I, Scurr M, Gardner K, et al. Phase II study of cediranib in patients with advanced gastrointestinal stromal tumors or soft-tissue sarcoma. Clin Cancer Res Off J Am Assoc Cancer Res. 2014 Jul 1;20(13):3603–3612.
   PubMed Web of Science ®Google Scholar
• D’Adamo DR, Anderson SE, Albritton K, et al. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J Clin Oncol Off J Am Soc Clin Oncol. 2005 Oct 1;23(28):7135–7142.
   PubMed Web of Science ®Google Scholar
• Verschraegen CF, Arias-Pulido H, Lee S-J, et al. Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the Axtell regimen. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2012 Mar;23(3):785–790.
   PubMed Web of Science ®Google Scholar
• Dickson MA, D’Adamo DR, Keohan ML, et al. Phase II trial of gemcitabine and docetaxel with bevacizumab in soft tissue sarcoma. Sarcoma. 2015;2015:532478.
   PubMedGoogle Scholar
• Hensley ML, Miller A, O’Malley DM, et al. Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: an NRG Oncology/Gynecologic Oncology Group study. J Clin Oncol Off J Am Soc Clin Oncol. 2015 Apr 1;33(10):1180–1185.
   PubMed Web of Science ®Google Scholar
• Agulnik M, Yarber JL, Okuno SH, et al. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2013 Jan;24(1):257–263.
   PubMed Web of Science ®Google Scholar
• Azizi AA, Haberler C, Czech T, et al. Vascular-endothelial-growth-factor (VEGF) expression and possible response to angiogenesis inhibitor bevacizumab in metastatic alveolar soft part sarcoma. Lancet Oncol. 2006 Jun;7(6):521–523.
   PubMed Web of Science ®Google Scholar
• Mir O, Boudou-Rouquette P, Larousserie F, et al. Durable clinical activity of single-agent bevacizumab in a nonagenarian patient with metastatic alveolar soft part sarcoma. Anticancer Drugs. 2012 Aug;23(7):745–748.
   PubMed Web of Science ®Google Scholar
• Ray-Coquard IL, Domont J, Tresch-Bruneel E, et al. Paclitaxel given once per week with or without bevacizumab in patients with advanced angiosarcoma: a randomized phase II trial. J Clin Oncol Off J Am Soc Clin Oncol. 2015 Sep 1;33(25):2797–2802.
   PubMed Web of Science ®Google Scholar
• Okuno S, Bailey H, Mahoney MR, et al. A phase 2 study of temsirolimus (CCI-779) in patients with soft tissue sarcomas: a study of the Mayo phase 2 consortium (P2C). Cancer. 2011 Aug 1;117(15):3468–3475.
   PubMed Web of Science ®Google Scholar
• Verschraegen CF, Movva S, Ji Y, et al. A phase I study of the combination of temsirolimus with irinotecan for metastatic sarcoma. Cancers. 2013;5(2):418–429.
   PubMedGoogle Scholar
• Yoo C, Lee J, Rha SY, et al. Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide. Invest New Drugs. 2013 Dec;31(6):1602–1608.
   PubMed Web of Science ®Google Scholar
• Mita MM, Mita AC, Chu QS, et al. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J Clin Oncol Off J Am Soc Clin Oncol. 2008 Jan 20;26(3):361–367.
   PubMed Web of Science ®Google Scholar
• Chawla SP, Staddon AP, Baker LH, et al. Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. J Clin Oncol Off J Am Soc Clin Oncol. 2012 Jan 1;30(1):78–84.
   PubMed Web of Science ®Google Scholar
• Demetri GD, Chawla SP, Ray-Coquard I, et al. Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy. J Clin Oncol Off J Am Soc Clin Oncol. 2013 Jul 1;31(19):2485–2492.
   PubMed Web of Science ®Google Scholar
• O’Reilly KE, Rojo F, She Q-B, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006 Feb 1;66(3):1500–1508.
   PubMed Web of Science ®Google Scholar
• Quek R, Wang Q, Morgan JA, et al. Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors. Clin Cancer Res Off J Am Assoc Cancer Res. 2011 Feb 15;17(4):871–879.
   PubMed Web of Science ®Google Scholar
• Kolb EA, Gorlick R, Maris JM, et al. Combination testing (stage 2) of the anti-IGF-1 receptor antibody IMC-A12 with rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer. 2012 May;58(5):729–735.
   PubMed Web of Science ®Google Scholar
• Schwartz GK, Tap WD, Qin L-X, et al. Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. Lancet Oncol. 2013 Apr;14(4):371–382.
   PubMed Web of Science ®Google Scholar
• ElNaggar AC, Hays JL, Chen JL. Addition of everolimus post VEGFR inhibition treatment failure in advanced sarcoma patients who previously benefited from VEGFR inhibition: a case series. PLoS One. 2016;11(6):e0156985.
   Google Scholar
• Bissler JJ, McCormack FX, Young LR, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med. 2008 Jan 10;358(2):140–151.
   PubMed Web of Science ®Google Scholar
• Davies DM, Johnson SR, Tattersfield AE, et al. Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis. N Engl J Med. 2008 Jan 10;358(2):200–203.
   PubMed Web of Science ®Google Scholar
• Dickson MA, Schwartz GK, Antonescu CR, et al. Extrarenal perivascular epithelioid cell tumors (PEComas) respond to mTOR inhibition: clinical and molecular correlates. Int J Cancer. 2013 Apr 1;132(7):1711–1717.
   PubMed Web of Science ®Google Scholar
• Wagner AJ, Malinowska-Kolodziej I, Morgan JA, et al. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. J Clin Oncol Off J Am Soc Clin Oncol. 2010 Feb 10;28(5):835–840.
   PubMed Web of Science ®Google Scholar
• Loizos N, Xu Y, Huber J, et al. Targeting the platelet-derived growth factor receptor alpha with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: implications as a potential therapeutic target. Mol Cancer Ther. 2005 Mar;4(3):369–379.
   PubMed Web of Science ®Google Scholar
• Ohnstad HO, Castro R, Sun J, et al. Correlation of TP53 and MDM2 genotypes with response to therapy in sarcoma. Cancer. 2013 Mar 1;119(5):1013–1022.
   PubMed Web of Science ®Google Scholar
• Bill KLJ, Garnett J, Meaux I, et al. SAR405838: a novel and potent inhibitor of the MDM2: p53 axis for the treatment of dedifferentiated liposarcoma. Clin Cancer Res Off J Am Assoc Cancer Res. 2016 Mar 1;22(5):1150–1160.
   PubMed Web of Science ®Google Scholar
• Obrador-Hevia A, Martinez-Font E, Felipe-Abrio I, et al. RG7112, a small-molecule inhibitor of MDM2, enhances trabectedin response in soft tissue sarcomas. Cancer Invest. 2015;33(9):440–450.
   PubMed Web of Science ®Google Scholar
• Ray-Coquard I, Blay J-Y, Italiano A, et al. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. Lancet Oncol. 2012 Nov;13(11):1133–1140.
   PubMed Web of Science ®Google Scholar
• Schwartz GK, LoRusso PM, Dickson MA, et al. Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (schedule 2/1). Br J Cancer. 2011 Jun 7;104(12):1862–1868.
   PubMed Web of Science ®Google Scholar
• Dickson MA, Tap WD, Keohan ML, et al. Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. J Clin Oncol Off J Am Soc Clin Oncol. 2013 Jun 1;31(16):2024–2028.
   PubMed Web of Science ®Google Scholar
• Luke JJ, D’Adamo DR, Dickson MA, et al. The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and results of a phase I dose-escalation clinical trial. Clin Cancer Res Off J Am Assoc Cancer Res. 2012 May 1;18(9):2638–2647.
   PubMed Web of Science ®Google Scholar
• Lubieniecka JM, de Bruijn DRH, Su L, et al. Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma. Cancer Res. 2008 Jun 1;68(11):4303–4310.
   PubMed Web of Science ®Google Scholar
• Hrzenjak A, Moinfar F, Kremser M-L, et al. Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo. Mol Cancer. 2010;9:49.
   PubMed Web of Science ®Google Scholar
• Fu S, Hou MM, Naing A, et al. Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2015 May;26(5):1012–1018.
   PubMed Web of Science ®Google Scholar
• Cassier PA, Lefranc A, Amela EY, et al. A phase II trial of panobinostat in patients with advanced pretreated soft tissue sarcoma. A study from the French Sarcoma Group. Br J Cancer. 2013 Aug 20;109(4):909–914.
   PubMed Web of Science ®Google Scholar
• Choy E, Flamand Y, Balasubramanian S, et al. Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma. Cancer. 2015 Apr 15;121(8):1223–1230.
   PubMed Web of Science ®Google Scholar
• Chu QS-C, Nielsen TO, Alcindor T, et al. A phase II study of SB939, a novel pan-histone deacetylase inhibitor, in patients with translocation-associated recurrent/metastatic sarcomas-NCIC-CTG IND 200†. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2015 May;26(5):973–981.
   PubMed Web of Science ®Google Scholar
• Thomas S, Aggarwal R, Jahan T, et al. A phase I trial of panobinostat and epirubicin in solid tumors with a dose expansion in patients with sarcoma. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2016 May;27(5):947–952.
   PubMed Web of Science ®Google Scholar
• Schmitt T, Mayer-Steinacker R, Mayer F, et al. Vorinostat in refractory soft tissue sarcomas – results of a multi-centre phase II trial of the German Soft Tissue Sarcoma and Bone Tumour Working Group (AIO). Eur J Cancer Oxf Engl 1990. 2016;64:74–82.
   PubMed Web of Science ®Google Scholar
• Tawbi -HA-H, Burgess MA, Crowley J, et al. Safety and efficacy of PD-1 blockade using pembrolizumab in patients with advanced soft tissue (STS) and bone sarcomas (BS): results of SARC028 – a multicenter phase II study. J Clin Oncol [Internet]. 2016 [cited 2016 Oct 11];34(suppl; abstr 11006). Available from: http://meetinglibrary.asco.org/content/168373-176
   Google Scholar
• George S, Barysauskas CM, Solomon S, et al. Phase 2 study of nivolumab in metastatic leiomyosarcoma of the uterus. J Clin Oncol [Internet]. 2016 [cited 2016 Oct 11];34(suppl; abstr 11007). Available from: http://meetinglibrary.asco.org/content/163028-176
   Google Scholar
• Paoluzzi L, Ghesani MV, Cacavio A, et al. Anti-PD1 therapy with nivolumab in sarcoma. J Clin Oncol [Internet]. 2016 [cited 2016 Oct 11];34(suppl; abstr 11047). Available from: http://meetinglibrary.asco.org/content/166876-176
   Google Scholar